Department of Pediatrics, Allergy and Immunology Section, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
Division of Immunology, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
Immunol Allergy Clin North Am. 2021 May;41(2):271-283. doi: 10.1016/j.iac.2021.01.002. Epub 2021 Mar 26.
Food allergy is a significant public health burden affecting around 10% of adults and 8% of children. Although the first peanut oral immunotherapy product received Food and Drug Administration approval in 2020, there is still an unmet need for more effective therapeutic options that minimize the risk of anaphylaxis, nutritional deficiencies, and patient's quality of life. Biologics are promising modalities, as they may improve compliance, target multiple food allergies, and treat other concomitant atopic diseases. Although omalizumab has been evaluated extensively, most biologics are more novel and have broader immunologic impact. Careful evaluation of their safety profile should therefore be conducted.
食物过敏是一个重大的公共卫生负担，影响着大约 10%的成年人和 8%的儿童。尽管首个花生口服免疫治疗产品于 2020 年获得了食品和药物管理局的批准，但仍需要更有效的治疗选择，以最大限度地降低过敏反应、营养缺乏和患者生活质量下降的风险。生物制剂是很有前途的治疗方法，因为它们可能提高患者的顺应性，针对多种食物过敏，并治疗其他伴随的特应性疾病。虽然奥马珠单抗已经得到了广泛的评估，但大多数生物制剂更为新颖，对免疫的影响也更广泛。因此，应该仔细评估它们的安全性。
